Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIME: Ivermectin-artemisinin for Malaria Eradication
NCT05605925Phase 4Unknown
- Sponsor
- Makerere University
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivermectin in malaria (2 arms), sponsored by Makerere University. Primary endpoint: Malaria transmission rates in a household at 28 days. Status: unknown.
02
Drugs
ivermectin
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05605925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605925.